Literature DB >> 23430345

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Swati Sikaria1, Josefine Heim-Hall, Elizabeth H Diaz, Ronald Williams, Kamelesh Sankhala, Brenda Laabs, Monica Mita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23430345     DOI： 10.1007/s11523-013-0267-8

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  20 in total

1.  A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Authors:  P Schöffski; P Reichardt; J-Y Blay; H Dumez; J A Morgan; I Ray-Coquard; N Hollaender; A Jappe; G D Demetri
Journal:  Ann Oncol       Date:  2010-05-27       Impact factor: 32.976

2.  Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee.

Authors:  Kingsley R Chin; Stephen J Barr; Carl Winalski; David Zurakowski; Gregory W Brick
Journal:  J Bone Joint Surg Am       Date:  2002-12       Impact factor: 5.284

3.  Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor.

Authors:  K Raile; A Höflich; U Kessler; Y Yang; M Pfuender; W F Blum; H Kolb; H P Schwarz; W Kiess
Journal:  J Cell Physiol       Date:  1994-06       Impact factor: 6.384

4.  Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.

Authors:  Hongwei Cheng; Paul W Clarkson; Dongxia Gao; Marina Pacheco; Yuzhuo Wang; Torsten O Nielsen
Journal:  Sarcoma       Date:  2010-10-13

5.  IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase.

Authors:  M G Myers; X J Sun; B Cheatham; B R Jachna; E M Glasheen; J M Backer; M F White
Journal:  Endocrinology       Date:  1993-04       Impact factor: 4.736

Review 6.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 7.  The role of mTOR inhibitors for treatment of sarcomas.

Authors:  Monica M Mita; Anthony W Tolcher
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

Review 8.  Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature.

Authors:  Chien-Feng Li; Jun-Wen Wang; Wen-Wei Huang; Chi-Chen Hou; Shih-Cheng Chou; Hock-Liew Eng; Ching-Nan Lin; Shih-Chen Yu; Hsuan-Ying Huang
Journal:  Am J Surg Pathol       Date:  2008-04       Impact factor: 6.394

9.  Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

Authors:  David Olmos; Sophie Postel-Vinay; L Rhoda Molife; Scott H Okuno; Scott M Schuetze; M Luisa Paccagnella; Gretchen N Batzel; Donghua Yin; Kathryn Pritchard-Jones; Ian Judson; Francis P Worden; Antonio Gualberto; Michelle Scurr; Johann S de Bono; Paul Haluska
Journal:  Lancet Oncol       Date:  2009-12-23       Impact factor: 41.316

Review 10.  Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.

Authors:  Vinod Ravi; Wei-Lien Wang; Valerae O Lewis
Journal:  Curr Opin Oncol       Date:  2011-07       Impact factor: 3.645
View more
  4 in total

Review 1.  mTOR inhibitors in urinary bladder cancer.

Authors:  R Pinto-Leite; R Arantes-Rodrigues; Nuno Sousa; P A Oliveira; L Santos
Journal:  Tumour Biol       Date:  2016-05-27

Review 2.  Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.

Authors:  Mehdi Brahmi; Armelle Vinceneux; Philippe A Cassier
Journal:  Curr Treat Options Oncol       Date:  2016-02

3.  Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.

Authors:  Sara Elena Rebuzzi; Massimiliano Grassi; Fabio Catalano; Michele Buscaglia; Rossella Bertulli; Camilla Satragno; Liliana Belgioia; Danila Comandini
Journal:  Anticancer Drugs       Date:  2020-01       Impact factor: 2.389

4.  Surgical Treatment of Sacroiliac Pigment Villous Nodular Synovitis: A Case Report and Literature Review.

Authors:  Jiashi Song; Kunpeng Jiang; Zhanhu Lv; Bing Liu
Journal:  Front Surg       Date:  2022-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.